Format

Send to

Choose Destination
Expert Opin Biol Ther. 2017 Jun;17(6):691-699. doi: 10.1080/14712598.2017.1316713. Epub 2017 Apr 13.

Advances in umbilical cord blood cell therapy: the present and the future.

Author information

1
a Centre for Allogeneic Stem Cell Transplantation , Karolinska University Hospital , Stockholm , Sweden.
2
b Department of oncology and Pathology , Karolinska Institutet , Stockholm , Sweden.
3
c Department of Clinical Science, Intervention and Technology , Karolinska Institutet , Stockholm , Sweden.
4
d Department of Applied Physics , Royal Institute of Technology , Stockholm , Sweden.
5
e Department of Immunology/Transfusion Medicine , Karolinska University Hospital , Stockholm , Sweden.

Abstract

Umbilical cord blood (UCB), previously seen as medical waste, is increasingly recognized as a valuable source of cells for therapeutic use. The best-known application is in hematopoietic stem cell transplantation (HSCT), where UCB has become an increasingly important graft source in the 28 years since the first umbilical cord blood transplantation (UCBT) was performed. Recently, UCB has been increasingly investigated as a putative source for adoptive cell therapy. Areas covered: This review covers the advances in umbilical cord blood transplantation (UCBT) to overcome the limitation regarding cellular dose, immunological naivety and additional cell doses such as DLI. It also provides an overview regarding the progress in adoptive cellular therapy using UCB. Expert opinion: UCB has been established as an important source of stem cells for HSCT. Successful strategies to overcome the limitations of UCBT, such as the limited cell numbers and naivety of the cells, are being developed, including novel methods to perform in vitro expansion of progenitor cells, and to improve their homing to the bone marrow. Promising early clinical trials of adoptive therapies with UCB cells, including non-immunological cells, are currently performed for viral infections, malignant diseases and in regenerative medicine.

KEYWORDS:

Cord blood transplantation; HLA; adoptive cell therapy; clinical trials; lymphocytes

PMID:
28379044
DOI:
10.1080/14712598.2017.1316713
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center